Bruker Cellular Analysis / Cellular Analysis Blog
Cellular Analysis Blog

Unlock the Phenome

Latest News
Vincent-Pai-TS-webinar-B-Cell-Diversity
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery

This webinar will be hosted live and available on-demand Wednesday, February 28, 2024 11:00 AM-12:00 PM Eastern Time (8:00 AM PT and 5:00 PM CET) As the demands and requirements for new antibodies continue to evolve, access to broader antibody sequence diversity coupled with a powerful screening technology is critical. Unlike hybridoma and display technologies …

Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery Read More »

scientific-reports-plasmablasts
Published in Scientific Reports: Understanding Antibody-Secreting Cells: A Closer Look at Cellular Dynamics with Optofluidic Precision

The behavior of early-minted antibody-secreting cells (ASC) or plasmablasts post-infection or vaccination plays a pivotal role in the immune response. Traditionally, long-lived plasma cells (LLPC) from the bone marrow are regarded as non-dividing, while blood ASCs are thought to be proliferative. Traditional technologies that average bulk data or measure surface phenotype alone miss critical functional …

Published in Scientific Reports: Understanding Antibody-Secreting Cells: A Closer Look at Cellular Dynamics with Optofluidic Precision Read More »

JITC-Car-t-manufacturing
Optimizing CAR-T Therapy Manufacturing Processes with Bruker’s IsoCode® Platform

In the rapidly evolving landscape of cancer treatment, Chimeric Antigen Receptor T cell (CAR-T) therapy has emerged as a promising strategy for patients with certain hematologic malignancies. However, the occurrence of relapse has proved challenging. In a recent publication in the Journal for ImmunoTherapy of Cancer, researchers from University College London investigated the potential capability …

Optimizing CAR-T Therapy Manufacturing Processes with Bruker’s IsoCode® Platform Read More »

Frontiers-in-Molecular-Medicine-CAR-T-workflow
Published in Frontiers in Molecular Medicine: Revolutionizing CAR-T Cell Manufacturing for Enhanced Therapeutic Responses with Bruker’s Single-Cell Instruments

In the rapidly evolving landscape of cancer treatment, chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking immunotherapeutic approach, garnering FDA approval in 2017. However, the journey from initial success to widespread efficacy has been marked by challenges, prompting researchers to continuously reevaluate and refine CAR-T manufacturing processes. A recent review published …

Published in Frontiers in Molecular Medicine: Revolutionizing CAR-T Cell Manufacturing for Enhanced Therapeutic Responses with Bruker’s Single-Cell Instruments Read More »

AET-poster
Navigating Challenges in B Cell Diversity by Leveraging Bruker’s Opto® Memory B Discovery Rabbit Sample Prep Kit on the Beacon® System

In antibody discovery, the screening of diverse antibody sequences is crucial to pinpoint the suitable antibodies for specific purposes. This challenge is particularly relevant in the context of rabbit antibodies, which are uniquely valuable reagents for basic research, diagnostics, and therapeutics development. Understanding Rabbit Antibodies Rabbits possess unique gene diversification strategies that result in antibodies …

Navigating Challenges in B Cell Diversity by Leveraging Bruker’s Opto® Memory B Discovery Rabbit Sample Prep Kit on the Beacon® System Read More »

cell-reports_2023_blog
Investigating Immune Evasion in Bordetella spp. Respiratory Pathogens with Bruker’s CodePlex® Platform

Developing vaccines and therapies against infectious diseases is a formidable task. To establish durable immune protection, a comprehensive understanding of the immune system’s response to infectious agents is essential. This involves immune monitoring to assess and predict protective responses, alongside monitoring cytokine levels for potential toxicities. Bordetella spp., respiratory bacterial pathogens, cause whooping cough—a persistent …

Investigating Immune Evasion in Bordetella spp. Respiratory Pathogens with Bruker’s CodePlex® Platform Read More »

cancer-immunology-research-ucla-blog
Navigating TCR-T Therapy: Insights from Single-Cell Proteomic Analysis

In cancer immunotherapy, TCR-T based cell therapies show promise for addressing specific types of solid tumors; however, variable patient responses and the potential for relapse indicate a need for improvement. A recent study published in Cancer Immunology Research by researchers at UCLA investigates clinical biomarkers for patient response in TCR-T therapy, shedding light on crucial …

Navigating TCR-T Therapy: Insights from Single-Cell Proteomic Analysis Read More »

science_HIV_blog
Unraveling the Mechanisms of HIV Vaccination to Inform Vaccine Development Strategies

Recent investigations into the mechanisms of HIV vaccination have uncovered promising new information that sheds light on why some vaccine trials have failed to show efficacy. While preclinical studies in nonhuman primates have suggested that vaccine-triggered CD8+ T cells are effective against HIV, several trials of HIV vaccines targeted to induce CD8+ T cell activation …

Unraveling the Mechanisms of HIV Vaccination to Inform Vaccine Development Strategies Read More »

blog_frontiers
Neoantigens Unveiled: Revolutionizing Cancer Immunotherapy with Optofluidic Technology

Neoantigens are self-antigens that arise in tumor cells as a result of tumor-specific alterations commonly caused by genomic mutations. Due to their high immunogenicity and foreign nature, they have emerged as promising targets for cell-based cancer therapeutics. While advances in next-generation sequencing, bioinformatics technologies, and machine learning algorithms have greatly accelerated neoantigen prediction, only a …

Neoantigens Unveiled: Revolutionizing Cancer Immunotherapy with Optofluidic Technology Read More »

blog_technology-spotlight---beacon
Technology Spotlight: How the Beacon® Optofluidic System is Powering the Future of Research, Development, Manufacturing, and Clinical Testing

Bruker’s Beacon® systems provide function-first assays at single cell resolution on a microfluidic platform, utilizing the power of light-driven, Opto-Electro Positioning (OEP) to drive targeted, selective cell cloning into Nanopen® chambers capable of continual media perfusion and cell culture, whilst supporting a variety of assays and assessments across the chip architecture. These include: Live Cell …

Technology Spotlight: How the Beacon® Optofluidic System is Powering the Future of Research, Development, Manufacturing, and Clinical Testing Read More »

blog_car-t_chip-library
How Function-First CAR-T Discovery Could Accelerate the Bench to Bedside Journey

While chimeric antigen receptor (CAR) T-cell therapies have significantly improved outcomes in hematological malignancies, attempts to translate this success to solid tumors have presented several challenges, such as inadequate efficacy and unacceptable toxicity. Researchers are continuously identifying new targets to overcome these challenges. However, in cell line development, translating their findings into viable, testable products …

How Function-First CAR-T Discovery Could Accelerate the Bench to Bedside Journey Read More »

Bruker_Linkedin_AET-2023
Explore Cutting-Edge Antibody Discovery with Bruker Cellular Analysis at the Antibody Engineering & Therapeutics Conference

We’re excited to announce that from December 13-16, Bruker Cellular Analysis will be an exhibitor at this year’s Antibody Engineering & Therapeutics Conference in San Diego. This premier event is dedicated to showcasing the latest advancements in antibody engineering, design, and selection. With a focus on diverse topics such as Neurodegenerative Diseases, Tumor Microenvironment in …

Explore Cutting-Edge Antibody Discovery with Bruker Cellular Analysis at the Antibody Engineering & Therapeutics Conference Read More »

Blog Post_Single-Cell Analysis Demonstrates Enhanced Immune Cell Function_jt
Published in Science Translational Medicine: Single-Cell Analysis Demonstrates Enhanced Immune Cell Function After Combination Therapy for Glioblastoma

Immunotoxin therapies have substantial potential and have already been demonstrated to improve outcomes in several types of cancers, but their efficacy has been limited. Cancer and tumor-associated cells oftentimes secrete proteins or express receptors that dampen immune activity to create an immunosuppressive environment that hinders therapeutic efficacy. Molecules that stimulate immune activity can help to …

Published in Science Translational Medicine: Single-Cell Analysis Demonstrates Enhanced Immune Cell Function After Combination Therapy for Glioblastoma Read More »

Blog Post_World's First On-Chip CAR Library_jt
New eBook: Unveiling a Breakthrough in Cancer Treatment

In the field of oncology, chimeric antigen receptor (CAR)-T cell therapy is a focal point of innovative research that has the potential to revolutionize cancer treatment. In our new eBook, “Creating the World’s First On-Chip CAR Library: How Cutting Edge Thinking and Technology Are Transforming the Cancer Treatment Landscape,” we offer you the opportunity to …

New eBook: Unveiling a Breakthrough in Cancer Treatment Read More »

Bruker_Linkedin_PEGS Europe_jt
Unveiling the Future of Protein and Antibody Research: The PEGS International Conference

The Protein & Antibody Engineering Summit (PEGS) International Conference, set to take place from November 14-16th at the Lisbon Congress Center in Lisbon, Portugal, is the largest protein & antibody engineering event in Europe, which has been described as “the best biologics technology meeting in Europe.” The team from Bruker Cellular Analysis will be at …

Unveiling the Future of Protein and Antibody Research: The PEGS International Conference Read More »

Bruker_Linkedin_SITC-2023
SITC SPOTLIGHT: Visit us at Booth 432 to Learn How Our Platforms are Addressing the Challenges of Developing Advanced Therapies

Bruker Cellular Analysis will be participating in the upcoming Society for Immunotherapy of Cancer (SITC) Conference, scheduled to take place on November 1-5 at the San Diego Convention Center. This conference stands as a leading global event that unites experts from the field of immunotherapy to advance the science, discover breakthroughs, and educate the world …

SITC SPOTLIGHT: Visit us at Booth 432 to Learn How Our Platforms are Addressing the Challenges of Developing Advanced Therapies Read More »

Blog_Antibody-Therapeutics_2023
Published in Antibody Therapeutics: Alpaca Single B Cell Interrogation and Heavy-Chain-Only Antibody Discovery on the Beacon® Platform

Researchers have used Bruker Cellular Analysis’ Optofluidic technology to establish the fastest high-resolution workflow for the discovery and engineering of VHH antibodies yet. Scientists developed a novel application leveraging Bruker’s optofluidic Beacon® platform to detect IgG2/3 antibodies from activated memory B cells derived from alpaca peripheral blood samples. B cells secreting PSMA-specific antibodies were recovered …

Published in Antibody Therapeutics: Alpaca Single B Cell Interrogation and Heavy-Chain-Only Antibody Discovery on the Beacon® Platform Read More »

Bruker_Linkedin_How-to-Speed-Up-Cell-Therapy-Development-Processes_jt
Upcoming Webinar: How to Speed Up Cell Therapy Development Processes

Although cellular immunotherapy can achieve good outcomes, only a small proportion of cancer patients are being treated via this approach, with extremely long waitlists. Furthermore, applying centralized manufacturing workflows to individualized products results in complex logistics, creating laborious and non-standardized processes that elevate drug costs. In this upcoming webinar on Thursday, October 26, 10:00-11:00 AM …

Upcoming Webinar: How to Speed Up Cell Therapy Development Processes Read More »

Bruker_Linkedin_Accelerating Antibody Discovery for Difficult Targets_jt
Upcoming Webinar: Accelerating Antibody Discovery for Difficult Targets

Scientists often use classical immunization strategies and hybridoma technologies to generate antibodies. However, when producing antibodies against poorly immunogenic targets, such as membrane proteins with short extracellular domains, these approaches achieve limited antibody diversity, making it difficult for scientists to select good candidates for pharmaceutical development. Innovative approaches that combine RNA immunization and single cell …

Upcoming Webinar: Accelerating Antibody Discovery for Difficult Targets Read More »

Blog-Post_-opto-b
Accelerate Antibody Discovery with the Opto® B Discovery Workflow on the Beacon® Platform

Unlock the future of antibody discovery with Opto® B Discovery on the Beacon® platform. This cutting-edge technology streamlines the process, drastically reducing time and cost. This state-of-the-art workflow leverages up to 4 optofluidic chips, characterizing single B cells quickly and efficiently. With the Opto® B Discovery workflow, the Beacon system can significantly speed up your …

Accelerate Antibody Discovery with the Opto® B Discovery Workflow on the Beacon® Platform Read More »

Unleashing-the-Future-of-Functional-Cell-Biology_Attending-Two-Major-Conferences
Unleashing the Future of Functional Cell Biology: Bruker Cellular Analysis to Attend Two Major Conferences

In the dynamic world of science and technology, Bruker Cellular Analysis is at the forefront, driving advancements in functional cell biology to improve human health. Our goal is to empower scientists to maximize the potential of every cell through pioneering optofluidic and proteomic technologies. We are excited to share our latest innovations and collaborations at …

Unleashing the Future of Functional Cell Biology: Bruker Cellular Analysis to Attend Two Major Conferences Read More »

spotlight-lambda_1200
Bruker Cellular Analysis Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference Bruker Cellular Analysis is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September …

Bruker Cellular Analysis Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows Read More »

Blog Post_Introducing Meteor_jt (1)
Introducing Meteor™ Chips on the IsoSpark™ Platform: Advancing Handsfree Quantitative Proteomics

In a significant development, we are pleased to introduce Meteor™ chips on the IsoSpark™ platform, marking a major step forward in high-throughput, quantitative, and automated bulk proteomics. This advancement promises to simplify research processes and expedite scientific progress. Meteor chips on the IsoSpark platform: The Advantages Automated Analysis and User-Friendly Meteor chips simplify proteomic workflows. …

Introducing Meteor™ Chips on the IsoSpark™ Platform: Advancing Handsfree Quantitative Proteomics Read More »

Blog-Post_Enhance-and-Expand-Anti-ID-Antibody-Diversity-and-Affinity_jt_jr
Upcoming Webinar 9/14/23: Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization

Biotherapeutics comprise a large portion of the treatment options for a wide range of conditions and account for almost half of drugs approvals in 2022. However, the pace of new biologic development has not grown in recent years in part because of the increasing complexity of drug targets and desired performance of these drugs. To …

Upcoming Webinar 9/14/23: Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization Read More »

Blog Post_Single-Cell Secretome & Bulk Analysis Platforms Reveal Functionality of CAR-T Cells_jt
Published in Blood: Unlocking the Potential of CD200R-CD28 Switch for Enhanced CAR-T Therapy in Multiple Myeloma

In a groundbreaking study, researchers at the University of Pennsylvania have identified a novel approach for advancing the effectiveness of CAR-T cell therapy for treating multiple myeloma (MM), a challenging form of cancer. In particular, the study investigates the phenomenon of CAR-T cell suppression, which often leads to relapses in MM patients treated with BCMA-specific …

Published in Blood: Unlocking the Potential of CD200R-CD28 Switch for Enhanced CAR-T Therapy in Multiple Myeloma Read More »

Unlocking-the-Power-of-Next-Generation-Antibody-Discovery_Strengthening-Preparedness-Against-Emerging-Diseases
Unlocking the Power of Next-Generation Antibody Discovery: Strengthening Preparedness Against Emerging Diseases

The world’s battle against emerging diseases and endemic threats demands rapid, effective solutions. The recent evolution of viruses like SARS-CoV-2 underscores the need for innovative antibody discovery methods that can keep pace with mutations. Introducing the Bruker Cellular Analysis Beacon® optofluidic system, a revolutionary tool that’s reshaping the fight against diseases. In our latest Application …

Unlocking the Power of Next-Generation Antibody Discovery: Strengthening Preparedness Against Emerging Diseases Read More »

Advancing-Cancer-Immunotherapy-with-Optofluidics-and-Proteomic-Barcoding-Technologies
Advancing Cancer Immunotherapy with Optofluidics and Proteomic Barcoding Technologies

The convergence of optofluidics and proteomic barcoding technologies marks a significant milestone in the evolution of cancer immunotherapy research. These cutting-edge tools empower scientists to unravel the complexities of immune responses, cellular behaviors, and functional proteomics with unprecedented speed and precision. As the pursuit of personalized medicine gains momentum, these technologies offer promise in guiding …

Advancing Cancer Immunotherapy with Optofluidics and Proteomic Barcoding Technologies Read More »

Upcoming-Webinar_Harnessing-the-Power-of-Single-Cell-Technologies-to-Identify-Biologically-Relevant-Parameters-Associated-with-Favorable-T-Cell-Mediated-Antitumor-Responses
Upcoming Webinar 9/11/23: Harnessing the Power of Single Cell Technologies to Identify Biologically Relevant Parameters Associated with Favorable T Cell-Mediated Antitumor Responses

In both research and clinical settings, the ability to identify which immune cells in a person’s body contribute to either cancer progression or clearance and their target specificity is of critical importance. Moreover, a more thorough understanding of the biological properties of T cells that correlate with clinical outcome is required and can help guide …

Upcoming Webinar 9/11/23: Harnessing the Power of Single Cell Technologies to Identify Biologically Relevant Parameters Associated with Favorable T Cell-Mediated Antitumor Responses Read More »

Blog Post_Cancer Immunotherapy Spotlight_jt
Cancer Immunotherapy Spotlight: How Functional Analysis is Shaping the Future

Over the last few decades, the scientific community has turned its gaze towards a promising field in the fight against cancer – immunology. The idea of harnessing the power of the immune system and functional cytokines to develop cancer treatments has been gaining traction.1 However, the cancer immunotherapy development pipeline is a long and winding …

Cancer Immunotherapy Spotlight: How Functional Analysis is Shaping the Future Read More »

Blog Post_CAR-TCR Summit_jt
CAR-TCR Spotlight: Visit Us at Booth #C31 to Learn More About How Single-Cell Functional Analysis is Advancing Cell Therapy Research

Bruker Cellular Analysis is looking forward to attending the 8th CAR-TCR Summit, the world’s pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types. From August 29 – September 1st in Boston, MA, this conference will feature groundbreaking presentations, panel discussions, and poster sessions focused on CAR-T and …

CAR-TCR Spotlight: Visit Us at Booth #C31 to Learn More About How Single-Cell Functional Analysis is Advancing Cell Therapy Research Read More »